相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets
Marcus W. Koch et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent
Marcus W. Koch et al.
JOURNAL OF NEUROLOGY (2020)
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Raja Kapoor et al.
LANCET NEUROLOGY (2018)
Cognition in multiple sclerosis: State of the field and priorities for the future
James F. Sumowski et al.
NEUROLOGY (2018)
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
Peter Feys et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
Robert W. Motl et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis
Ralph H. B. Benedict et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis
Peter Feys et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis
Robert W. Motl et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis
Ralph H. B. Benedict et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Comparative utility of disability progression measures in PPMS Analysis of the PROMiSe data set
Marcus W. Koch et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred Lublin et al.
LANCET (2016)
Treatment trials in progressive MS-current challenges and future directions
Marcus W. Koch et al.
NATURE REVIEWS NEUROLOGY (2013)
Cognitive impairment in multiple sclerosis
Nancy D. Chiaravalloti et al.
LANCET NEUROLOGY (2008)
Disability as an outcome in MS clinical trials
G. C. Ebers et al.
NEUROLOGY (2008)
Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis
C Tortorella et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2005)
Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial
OR Hommes et al.
LANCET (2004)
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
JA Cohen et al.
NEUROLOGY (2002)
Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts
C Liu et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2000)
Kurtzke scales revisited: the application of psychometric methods to clinical intuition
J Hobart et al.
BRAIN (2000)
分享论文
